Business Context and Reporting Period
This Form 8-K is filed by Onconova Therapeutics, Inc. (ONTX) on November 19, 2019. The report addresses a notice received from the Nasdaq Staff regarding the Company's failure to meet the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, or debt figures. It specifically reports on stockholders' equity deficits as follows:
- March 31, 2019: Approximately $(1.5) million
- June 30, 2019: Approximately $(4.6) million
- September 30, 2019: Approximately $(6.0) million
The Nasdaq minimum stockholders' equity requirement is $2.5 million.
Material Changes and Events
On November 19, 2019, the Company received a letter from Nasdaq stating it had failed to regain compliance with the Stockholders' Equity Requirement by the deadline of November 18, 2019. Consequently, Nasdaq determined to seek delisting of the Company's securities unless a hearing is requested. The Company intends to request a hearing before the Nasdaq Hearings Panel to seek an additional extension of up to 180 calendar days to regain compliance.
Outlook, Risks, and Management Commentary
Management is working with advisors to prepare a plan of compliance for review by the Hearings Panel. The filing highlights significant risks associated with potential delisting:
- Difficulty in buying or selling securities and obtaining accurate quotations.
- Potential material decline in the price of the Company's securities.
- Impaired ability to raise capital.
Investor Verification Checklist
- Verify the status of the hearing request before the Nasdaq Hearings Panel.
- Monitor the Company's plan of compliance to address the equity deficit.
- Assess the impact of the equity deficit on the Company's ability to raise capital.
- Review subsequent filings for updates on the delisting determination or extension grants.